Kardigan Inc., a clinical-stage cardiovascular drug developer, made a strong entrance on the Nasdaq on Thursday, with shares closing at $22, a 37.5% gain from its initial public offering price of $16. The company raised $400 million in an upsized offering, marking one of the largest biotech IPOs of the year and signaling a resurgence in investor confidence for well-funded drug developers.
The stock opened at $16.25, touched a high of $23.75 during the session, and saw 5.7 million shares change hands. After-hours trading at 6:22 p.m. EDT saw the stock at $21.22, still comfortably above the offer price. The company's market capitalization stood near $1.93 billion at the close.
Kardigan is the fourth biotech firm this year to raise at least $400 million in its IPO, according to industry tracker BioPharma Dive, joining a select group that includes Parabilis Medicines, Kailera Therapeutics, and Generate:Biomedicines, which raised a similar amount in February. This wave of large offerings suggests that the IPO window for biotech is reopening, particularly for companies with advanced clinical programs and strong institutional backing.
The company's pipeline features three late-stage cardiovascular candidates: danicamtiv for genetic dilated cardiomyopathy, ataciguat for moderate calcific aortic valve stenosis, and tonlamarsen for acute severe hypertension. All three are in Phase 2b or Phase 2b/3 trials, which are designed to evaluate safety and efficacy before moving to pivotal studies. Kardigan's CEO, Tassos Gianakakos, and Chief Medical Officer, Jay Edelberg, previously worked at MyoKardia, which was acquired by Bristol Myers Squibb in a $13 billion deal in 2020, a track record that has drawn investor attention.
Despite the strong debut, the company faces significant risks. In its prospectus, Kardigan warned that its cash, cash equivalents, and marketable securities as of March 31 are insufficient to fund operations for at least 12 months from May 26, raising "substantial doubt" about its ability to continue as a going concern without additional financing. The company also cautioned that drug development is inherently uncertain, with trials susceptible to failure at any stage, and that future stock sales could dilute existing shareholders.
The broader biotech sector saw modest gains on Thursday, with the SPDR S&P Biotech ETF rising 0.9% and the iShares Nasdaq Biotechnology ETF adding 0.2% in evening trading. However, the Nasdaq is closed on Friday for the Juneteenth holiday, meaning the true test for Kardigan's stock may come next week, when investors shift focus from first-day demand to the company's upcoming data readouts, expected in the first half of 2027.
The IPO was underwritten by J.P. Morgan, Jefferies, Leerink Partners, and TD Securities, and is expected to close on June 22. Kardigan's debut underscores a cautious but active market for biotech IPOs, where investors are selective but willing to back companies with scale, advanced pipelines, and experienced management teams.
